Is the headline price the whole bill?
Ask what the price includes, what changes after an offer ends and what you will pay again.
A starting price is a prompt for questions. Ask for a written total for the plan being discussed.
A low starting price tells me the full cost of peptide care.
The assumption falls shortRead the price and its conditions together.
As of September 2026, a weight or diabetes medicine’s price varies with the payment route: cash, insurance or a government program.
A real price still has limits
Semaglutide is a type 2 diabetes medicine sold as Ozempic; the price example here concerns its injection pen.
Strength means the amount of the ingredient in a product. The amounts below identify the products in the price offer; ask the person prescribing which product fits your care.
As of September 2026, a semaglutide (Ozempic) pen cash offer starts at $199 for the first two monthly fills.
The offer applies to U.S. adults described as “new self-pay patients” and covers the 0.25 mg strength as well as the 0.5 mg strength.
It ends on December 31, 2026.
After the first two monthly fills, the listed monthly price is $349 for any of three strengths: 0.25 mg, 0.5 mg and 1 mg.
The 2 mg strength costs $499 a month after those first two fills.
The offer does not allow you to ask insurance to repay the cost or count it towards your deductible, the amount you pay before insurance begins paying.
The recorded terms do not explain whether “new self-pay” means new to this medicine or new to paying outside insurance. Before relying on the price, ask the pharmacy to confirm whether you qualify.
That is an example for a named medicine, not a price for every peptide or for care aimed at living longer.
Ask what you would pay after the first offer, with your exact product and payment route.
Ask which use your plan covers
Start with the medicine’s name and the reason it would be prescribed. Ask the insurer whether that use is covered and what paperwork is needed.
As of September 2026, Medicare drug plans may cover these medicines for a recognised medical use other than weight loss, such as treating type 2 diabetes or reducing certain heart risks.
That means the medicine is prescribed for a health problem it is accepted to treat. Ask your plan whether it covers your exact medicine for your diagnosis and who will send the request for payment approval.
GLP-1, a body signal, plays a part in hunger and blood sugar; some medicines for diabetes and weight copy its action.
When a cost is covered, the part you pay is called your copay.
For eligible drug-plan members, the Medicare GLP-1 Bridge provides covered weight-loss medicines at a $50 copay each month, as of September 2026.
The program starts on July 1, 2026, and ends on December 31, 2027, with payments kept separate from your usual Medicare drug coverage.
In 2026, a single service for the Bridge program checks payment requests and pays pharmacies, instead of using your drug plan’s usual payment process.
The $50 does not count towards your usual yearly cap on Medicare drug costs.
The program gives no extra price help to people on low incomes.
As of September 2026, the Bridge requires a prescription and approval for payment.
You also need drug coverage through either a separate Medicare drug plan or a Medicare Advantage plan that qualifies.
Ask your doctor and pharmacy to check the Bridge rules and send the request to the program. Ask your plan to confirm that your type of coverage qualifies.
The health rules use body mass index, or BMI, which is worked out using your height and weight. Ask your doctor for yours and which rule applies to you.
As of September 2026, adults aged 18 or older can meet the Bridge health rules with a BMI of 35 or higher, or at lower BMI levels with certain health problems.
At a BMI of 30 or higher, the rules include a specified kind of heart failure or kidney disease that has reached stage 3a or later.
High blood pressure still uncontrolled despite two blood-pressure medicines is another qualifying condition at that BMI.
At a BMI of 27 or higher, qualifying problems include pre-diabetes, a heart attack in the past, a stroke in the past, or artery disease causing symptoms in the limbs.
Type 2 diabetes, moderate or severe breathing pauses during sleep, called sleep apnea, and a specified liver disease with moderate or advanced scarring rule out Bridge access.
These conditions use the usual Medicare drug-coverage route instead.
If your Medicare drug plan made a payment for a GLP-1 medicine during 2026, you are ineligible for the Bridge during 2026.
The prescription must also be part of an ongoing plan for nutrition and physical activity.
These are starting checks, not a promise of coverage. Ask the doctor to check the exact heart, blood-pressure, kidney or liver diagnosis against the full rules linked here.
A prescription to reduce the risk of certain heart problems also goes through your usual Medicare drug plan, rather than the Bridge.
Put the whole plan on paper
- Visit and follow-up
What is the first visit fee? Are later visits included or charged separately?
- Medicine
Is this a usual price or an offer? What will the same product cost after the offer ends?
- Tests and delivery
Which tests are needed? Are lab work, supplies or delivery separate charges?
- Renewal and cancellation
What renews, when does it renew and how can I cancel? What happens to payment if no medicine is prescribed?
Compare the same parts of each plan. A medicine-only quote and a visit-and-medicine quote need different questions.